|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2009-8-28
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Preclinical models have demonstrated the efficacy of granulocyte-macrophage colony-stimulating factor-secreting cancer immunotherapies (GVAX platform) accompanied by immunotherapy-primed lymphocytes after autologous stem cell transplantation in hematologic malignancies. We conducted a phase 2 study of this combination in adult patients with acute myeloid leukemia. Immunotherapy consisted of autologous leukemia cells admixed with granulocyte-macrophage colony-stimulating factor-secreting K562 cells. "Primed" lymphocytes were collected after a single pretransplantation dose of immunotherapy and reinfused with the stem cell graft. Fifty-four subjects were enrolled; 46 (85%) achieved a complete remission, and 28 (52%) received the pretransplantation immunotherapy. For all patients who achieved complete remission, the 3-year relapse-free survival (RFS) rate was 47.4% and overall survival was 57.4%. For the 28 immunotherapy-treated patients, the RFS and overall survival rates were 61.8% and 73.4%, respectively. Posttreatment induction of delayed-type hypersensitivity reactions to autologous leukemia cells was associated with longer 3-year RFS rate (100% vs 48%). Minimal residual disease was monitored by quantitative analysis of Wilms tumor-1 (WT1), a leukemia-associated gene. A decrease in WT1 transcripts in blood was noted in 69% of patients after the first immunotherapy dose and was also associated with longer 3-year RFS (61% vs 0%). In conclusion, immunotherapy in combination with primed lymphocytes and autologous stem cell transplantation shows encouraging signals of potential activity in acute myeloid leukemia (ClinicalTrials.gov: NCT00116467).
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/19556425-10466632,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19556425-10707999,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19556425-10807763,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19556425-11134207,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19556425-11877265,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19556425-12357365,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19556425-12393746,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19556425-12406915,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19556425-12586798,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19556425-12714526,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19556425-12947071,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19556425-14534335,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19556425-14569560,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19556425-15147374,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19556425-15534356,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19556425-15534358,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19556425-16410826,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19556425-16522812,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19556425-16740763,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19556425-17169779,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19556425-17606721,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19556425-18316569,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19556425-18443273,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19556425-18591543,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19556425-7808487,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19556425-8078551,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19556425-8422457,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19556425-9242568,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19556425-9376578,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19556425-9718378,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19556425-9834301
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1528-0020
|
|
pubmed:author |
pubmed-author:AlyeaEdwin PEP,
pubmed-author:BorrelloIvan MIM,
pubmed-author:DamonLloyd ELE,
pubmed-author:DeAngeloDaniel JDJ,
pubmed-author:HegeKristen MKM,
pubmed-author:LevitskyHyam IHI,
pubmed-author:LinkerCharles ACA,
pubmed-author:MaslyarDaniel JDJ,
pubmed-author:ObiII,
pubmed-author:SherDorieD,
pubmed-author:StockWendyW,
pubmed-author:StoneRichard MRM
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
27
|
|
pubmed:volume |
114
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1736-45
|
|
pubmed:dateRevised |
2010-9-24
|
|
pubmed:meshHeading |
pubmed-meshheading:19556425-Adult,
pubmed-meshheading:19556425-Cell Line, Tumor,
pubmed-meshheading:19556425-Disease-Free Survival,
pubmed-meshheading:19556425-Female,
pubmed-meshheading:19556425-Granulocyte-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:19556425-Humans,
pubmed-meshheading:19556425-Immunotherapy,
pubmed-meshheading:19556425-Leukemia, Myeloid, Acute,
pubmed-meshheading:19556425-Male,
pubmed-meshheading:19556425-Middle Aged,
pubmed-meshheading:19556425-Remission Induction,
pubmed-meshheading:19556425-Stem Cell Transplantation,
pubmed-meshheading:19556425-Transplantation, Autologous,
pubmed-meshheading:19556425-Treatment Outcome
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML).
|
|
pubmed:affiliation |
The Johns Hopkins University, Baltimore, MD 21231, USA
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II,
Research Support, N.I.H., Extramural
|
